IOLCP
IOL Chemicals and Pharmaceuticals Limited (IOLCP) Stock Analysis
IOL Chemicals and Pharmaceuticals Limited manufactures ibuprofen API and specialty chemicals for global pharma customers. It is a major global supplier of the active ingredient and related intermediates. The company also has formulation businesses. It is a listed API-led pharma firm.
Healthcare › Drug Manufacturers - Specialty & Generic
₹194.70
-3.21% 1W | +100.00% 52W
Market Cap
5.7k CR
P/E Ratio
34
52W High
₹224
52W Low
₹67.2
Div. Yield
0.51%
Beta
0.5
50 DMA
₹191.4
200 DMA
₹125.8
Profit Margin
6.7%
Inst. Own.
1.8%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 563 | 545 | 520 | 504 | 502 | 526 | 523 | 528 | 552 | 568 | 580 | 619 | 756 |
| Expenses | 491 | 481 | 476 | 454 | 451 | 484 | 476 | 465 | 490 | 510 | 523 | 527 | 653 |
| Operating Profit | 73 | 64 | 44 | 50 | 51 | 42 | 47 | 63 | 62 | 57 | 57 | 92 | 103 |
| OPM % | 13% | 12% | 9% | 10% | 10% | 8% | 9% | 12% | 11% | 10% | 10% | 15% | 14% |
| Other Income | 7 | 7 | 8 | 8 | 7 | 6 | 4 | 5 | 7 | 7 | -6 | 2 | 8 |
| Interest | 4 | 4 | 4 | 3 | 2 | 4 | 4 | 4 | 4 | 3 | 4 | 3 | 4 |
| Depreciation | 14 | 16 | 16 | 16 | 17 | 18 | 19 | 19 | 20 | 20 | 20 | 20 | 21 |
| Profit before tax | 61 | 51 | 32 | 37 | 40 | 26 | 28 | 45 | 46 | 40 | 28 | 71 | 87 |
| Tax % | 25% | 26% | 28% | 26% | 24% | 26% | 26% | 30% | 25% | 26% | 25% | 25% | 26% |
| Net Profit | 46 | 38 | 23 | 28 | 30 | 19 | 21 | 31 | 34 | 30 | 21 | 53 | 64 |
| EPS in Rs | 1.56 | 1.29 | 0.79 | 0.94 | 1.02 | 0.65 | 0.70 | 1.07 | 1.16 | 1.02 | 0.70 | 1.81 | 2.19 |
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|
| Sales | 2,184 | 2,217 | 2,133 | 2,079 | 2,319 | 2,524 |
| Expenses | 1,925 | 1,991 | 1,902 | 1,877 | 2,049 | 2,213 |
| Operating Profit | 259 | 226 | 231 | 202 | 270 | 310 |
| OPM % | 12% | 10% | 11% | 10% | 12% | 12% |
| Other Income | 17 | 25 | 30 | 22 | 9 | 11 |
| Interest | 8 | 16 | 16 | 15 | 15 | 14 |
| Depreciation | 43 | 46 | 63 | 72 | 80 | 82 |
| Profit before tax | 225 | 189 | 182 | 138 | 184 | 226 |
| Tax % | 25% | 26% | 26% | 27% | 25% | |
| Net Profit | 168 | 139 | 134 | 101 | 138 | 168 |
| EPS in Rs | 5.71 | 4.74 | 4.58 | 3.44 | 4.69 | 5.72 |
| Dividend Payout % | 14% | 17% | 22% | 23% | 21% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 2.0% | – | – |
| Profit CAGR | 2.0% | – | – |
Shareholding Pattern
Promoters52.62%
FIIs2.25%
DIIs0.05%
Public45.10%
Promoters52.62%
FIIs2.08%
DIIs0.03%
Public45.26%
Promoters57.48%
FIIs1.72%
DIIs0.02%
Public40.78%
Promoters62.28%
FIIs4.87%
DIIs0.43%
Public32.41%
Promoters62.28%
FIIs7.26%
DIIs0.30%
Public30.16%
Promoters48.19%
FIIs2.43%
DIIs0.23%
Public49.15%
Promoters48.19%
FIIs1.40%
DIIs0.29%
Public50.11%
Promoters52.62%
FIIs1.47%
DIIs0.07%
Public45.84%
Promoters57.48%
FIIs1.72%
DIIs0.02%
Public40.78%
Promoters62.28%
FIIs7.26%
DIIs0.30%
Public30.16%
IOLCP
Holdings Analysis
Key strengths & risk signals
60
Overall
35
Fundamental
86
Technical
Risks (1)
Cannot calculate PEG - insufficient growth data.
Strengths (4)
MODERATE STABILITY! 2 revenue dips in history. Acceptable but monitor closely.
BULLISH TREND! 50-day average (191.4) is above 200-day average (125.8) - positive signal.
EXCELLENT YEAR! Stock gained 100.0% in the last year.
BULLISH SENTIMENT! In last 30 days: 15 up days, 15 down days. Avg volume on up days: 4,754,403 vs down days: 3,103,859. Ratio: 1.53x
Fundamental & Technical Analysis
60Overall
35Fundamental
86Technical
Fundamental Breakdown
Growth Quality
7/30
Revenue CAGR: 1.6% (SLOW, 5/15). Profit CAGR: -0.4% (DECLINING, 2/15).
Profit Margin
3/10
LOW MARGIN! 6.7% profit margin - thin profits.
PEG Valuation
1/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.51% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
5/20
TOO MUCH PUBLIC HOLDING! 48.02% public ownership - higher volatility risk.
Stability Index
6/10
MODERATE STABILITY! 2 revenue dips in history. Acceptable but monitor closely.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (191.4) is above 200-day average (125.8) - positive signal.
Price Position
8/10
STRONG POSITION! Current price (194.7) is above both moving averages.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
10/10
EXCELLENT YEAR! Stock gained 100.0% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 15 up days, 15 down days. Avg volume on up days: 4,754,403 vs down days: 3,103,859. Ratio: 1.53x
RSI
3/5
NEUTRAL! RSI at 47.2 - balanced momentum.
52W Range
5/5
STRONG! Trading at 81.3% of 52W range - near yearly highs.
Momentum
3/5
MIXED MOMENTUM! Price growth is inconsistent - -3.2% (1 week), 0.1% (1 month), 31.2% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.50 - stable stock, less market risk.
IOLCP
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-09-17 | Concall PDF | |
| Q4FY262026-05-28 | Concall PDF | |
| Q3FY262026-02-18 | Concall PDF | |
| Q2FY262025-11-19 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IOLCP | ₹194.70 | 34 | 6.7% | 1.6% | -0.4% | +100.0% | 60 | BREAKDOWN | +90.0% | +21.1% | +37.1% | +22.1% |
| FDC | ₹356.20 | 19.8 | 13.4% | 6.8% | 13.2% | -19.7% | 72 | BREAKOUT | +9.1% | +28.1% | +3.0% | +14.2% |
| INNOVACAP | ₹1,019.80 | 37.9 | 8.8% | 20.1% | 27.5% | +27.4% | 72 | BREAKDOWN | +42.3% | +15.7% | +34.0% | +5.2% |
| SPARC | ₹188.60 | 3.9 | 83.0% | -45.3% | – | +45.5% | 61 | BOUNCE FROM SUPPORT | -59.9% | -101.2% | +315.6% | -97.8% |
| MOREPENLAB | ₹123.90 | 48.4 | 7.2% | 8.4% | 34.9% | +161.2% | 72 | BREAKDOWN | +427.1% | +259.2% | +34.1% | +17.6% |
| BLISSGVS | ₹652.00 | 51.7 | 13.5% | 7.2% | 22.1% | +334.4% | 73 | BREAKDOWN | +16.5% | +40.7% | +37.6% | +11.1% |
| AARTIPHARM | ₹873.60 | 37.2 | 10.4% | -2.6% | -3.3% | +1.3% | 59 | CONSOLIDATING UP | +65.4% | +24.5% | +38.7% | -8.0% |
| SUVEN | ₹303.60 | – | – | -19.3% | – | +49.1% | 55 | BREAKDOWN | +147.8% | +179.8% | +89.5% | +140.0% |
Data from TradeAlone · Updated daily
IOLCP News
Iol Chemicals and Pharmaceuticals Limited (iolcp) Q1 FY27: Record Revenue and Margin Expansion2026-08-10Iol Chemicals and Pharmaceuticals Limited Q4 & FY26: Revenue Up 11.5%, PAT Surges 68.2%2026-05-21Iol Chemicals and Pharmaceuticals Limited (iolcp) Q4 & FY26 Results: Highest-ever Quarterly Revenue with 15%+ Ebitda Margin2026-05-20
